1.6 Exenatide BID vs. Insulin Lispro TIDM Added to Titrated Insulin Glargine QD in Metformin-Treated T2DM Patients Resulted in Similar Glycemic Control but Weight Loss and Less Hypoglycemia: The 4B Study (70-OR)

Addition of prandial to basal insulin is the current strategy when A1C is elevated above target, but at the cost of hypoglycemia (hypo) and weight gain. We examined Basal insulin glargine (IG) + Exenatide BID Treatment (BET) or Basal IG + mealtime Bolus insulin lispro (IL) Treatment (BBT) in patients (pts) on metformin uncontrolled on intensified IG.